Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients With SA-AKI

NCT04411472 is registered in ClinicalTrials.gov with AM-Pharma as lead sponsor.

NCT NCT04411472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04411472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients With SA-AKI
Lead sponsor
AM-Pharma
Phase
Phase 3
Overall status
Terminated
Start date
November 2, 2020
Completion date
August 18, 2022
Enrollment
676 (actual)
Sites
122

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury due to sepsis